Anti-PD-1 antibody treatment for melanoma
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference3 articles.
1. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis;Beaver;Lancet Oncol,2018
2. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab;Hodi;J Clin Oncol,2016
3. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma;Ribas;JAMA,2016
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy;Best Practice & Research Clinical Gastroenterology;2024-08
2. Immunomodulatory Peptides for Tumor Treatment;Advanced Healthcare Materials;2024-05-04
3. Identification of Anti-PD-1 Immunotherapy Response-related Features as Prognostic Biomarkers in Melanoma and Associated with Tumor Immune Microenvironment;J BIOL REG HOMEOS AG;2024
4. CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing;Proceedings of the National Academy of Sciences;2023-09-18
5. The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials;Experimental and Therapeutic Medicine;2023-03-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3